PLK1 and neoplasm: The convergence of these results emphasizes the interplay between tumor cell proliferation and immune responses, underscoring the potential for therapeutic strategies that leverage CD4+ T cells to enhance anti-tumor immunity [64] while targeting key cell cycle regulators such as PLK1, CDK1, and CDC20.